Qube Research & Technologies (QRT)
AVDL

Qube Research & Technologies (QRT)’s Avadel Pharmaceuticals AVDL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-585,102
Closed -$12.6M – 3528
2025
Q4 		$12.6M Buy
585,102
+542,121
+1,261% +$10.5M 0.01% 1190
2025
Q3 		$656K Sell
42,981
-76,976
-64% -$1M ﹤0.01% 2642
2025
Q2 		$1.06M Buy
+119,957
New +$1.05M ﹤0.01% 2435
2024
Q4 		– Sell
-225,970
Closed -$2.96M – 3449
2024
Q3 		$2.96M Buy
+225,970
New +$3.44M ﹤0.01% 1605
2023
Q4 		– Sell
-53,523
Closed -$551K – 4329
2023
Q3 		$551K Buy
+53,523
New +$717K ﹤0.01% 1990
2022
Q1 		– Sell
-160,206
Closed -$1.29M – 2432
2021
Q4 		$1.29M Buy
+160,206
New +$1.46M 0.01% 1044
2020
Q4 		– Sell
-18,039
Closed -$91K – 1799
2020
Q3 		$91K Sell
18,039
-20,188
-53% -$147K ﹤0.01% 1502
2020
Q2 		$309K Buy
38,227
+27,133
+245% +$239K ﹤0.01% 1285
2020
Q1 		$88K Buy
+11,094
New +$85.2K ﹤0.01% 980

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AVDL Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 585,102 shares — an estimated $12.6M sold.

Qube Research & Technologies (QRT) first reported a position in AVDL in Q1 2020 and held it in 9 quarters. The position peaked at $12.6M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Qube Research & Technologies (QRT) reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 585,102 Avadel Pharmaceuticals shares in Q1 2026, an estimated $12.6M.
  • Qube Research & Technologies (QRT) first reported a position in Avadel Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • Qube Research & Technologies (QRT)'s Avadel Pharmaceuticals position peaked at $12.6M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.